Diagnosis & Treatment Blogs

Our lung tissue is made of different kinds of cells, including neuroendocrine cells. If these cells develop changes in their genome, they can begin to grow out of control and

The point at which lung cancer is diagnosed plays a key role in treatment and survival. The average 5-year survival rate for lung cancer diagnosed while still localized (stage I)

Participating in a clinical trial gives patients the ability to try the newest treatments that otherwise are not available. There are many ongoing clinical trials testing new lung cancer treatments, including targeted therapies, chemotherapy, radiation therapy, and immunotherapy, alone and in combination.

Paul K. Paik, MD, medical oncologist and researcher at Memorial Sloan Kettering Cancer Center and a member of LUNGevity’s Scientific Advisory Board, sat down to talk about what squamous cell lung cancer is and where we stand with treatment options for this disease.

Communication is critical to a positive doctor-patient relationship. Knowing the right questions to ask helps ensure you leave your appointments with the information and answers

For World Cancer Day this year, the Union for International Cancer Control presents the #CloseTheCareGap initiative. February 4, 2023 will be a day focused on promoting equity in

Researchers have made tremendous progress in treating lung cancer by identifying key mutations in genes that drive the growth of lung cancer. Once these “driver” mutations are

While targeted therapies have emerged in the past decade to improve treatment of non-small cell lung cancer (NSCLC) with some types of driver mutations (such as EGFR and ALK), lung

On June 1st, 2022, LUNGevity Foundation hosted a Facebook Live to discuss our manuscript titled “The 2021 Global Lung Cancer Therapy Landscape” published in the Journal of Thoracic

Palliative care, or supportive care, often misunderstood as only end-of-life care, improves patients' quality of life while undergoing treatment. The goal of palliative care is to

Lung cancer continues to be the number-one cause of cancer deaths in the United States. In the past decade, we have seen great improvements in the treatment of metastatic lung

On May 28, 2021, the United States Food & Drug Administration (FDA) approved sotorasib as the first targeted therapy for patients with KRAS G12C-positive non-small cell lung cancer (NSCLC).